Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Avelumab is a fully human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. By binding to PD-L1, it blocks its interaction with the inhibitory T-cell receptor PD-1 and B7.1, thereby removing suppression of T-cell activity and promoting adaptive antitumor immune responses. Unlike some other anti-PD-L1 antibodies, avelumab has a wild-type IgG1 Fc region, enabling engagement with Fc-γ receptors on natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab is approved for the treatment of metastatic Merkel cell carcinoma (MCC), metastatic urothelial carcinoma (UC), and advanced renal cell carcinoma (RCC) in combination with axitinib. It was developed by Merck KGaA and Pfizer[3][5][6].
- Brand names
- Bavencio
- Other names
- avelumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab.